曲美布汀+莫沙必利对功能性消化不良患者的治疗效果

Effect of Trimebutine and Mosapride on Patients With Functional Dyspepsia

目的分析曲美布汀+莫沙必利对功能性消化不良(FD)患者的治疗效果。方法选择本院于2014年1月—2018年1月收治的58例FD患者为研究主体。划分为A组和B组,均是29例。A组给予曲美布汀+莫沙必利联合治疗,B组给予莫沙必利单纯治疗。对比治疗效果。结果 A组的治疗总有效率为93.10%,B组为72.41%,对比差异具有统计学意义(P<0.05)。A组的餐后饱胀、上腹烧灼感、上腹痛与恶心等症状评分均低于B组(P<0.05)。A组的不良反应发生率为6.90%,B组为10.34%,对比差异无统计学意义(P>0.05)。结论为FD患者行曲美布汀+莫沙必利治疗可改善临床症状,减少不良反应,具有较佳的治疗效果。

Objective To analyze the efect of trimebutine and mosapride on patients with functional dyspepsia （FD）. Methods 58 FD patients admitted in our hospital from January 2014 to January 2018 were selected as the research subjects. They were divided into group A and group B, 29 cases in each group. The group A was treated with trimebutine and mosapride, and the group B was given simple treatment of mosapride. The clinical efects were compared. Results The efective rate of treatment in group A was 93.10%, and the group B was 72.41%, the difference was statistically significant （P 〈 0.05）. The scores of postprandial fullness, upper abdominal burning sensation, upper abdominal pain and nausea in group A were lower than those in group B （P 〈 0.05）. The incidence of adverse reactions in group A was 6.90%, group B was 10.34%, there was no diference between the two groups （P 〉 0.05）. Conclusion Trimebutine and mosapride on patients with FD can improve clinical symptoms, reduce adverse reactions, and have better clinical efects.